For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future. INCLUDED IN THIS TRENDLINE Biotech startup funding gap widens despite rebound in VC investment ‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
